✦ LIBER ✦

Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate

✍ Scribed by E. James Seidmon; Donald L. Trump; Willi Kreis; Stephen W. Hall; Michael R. Kurman; S. Peter Ouyang; Jane Wu; Alton B. Kremer

Book ID: 112729655
Publisher: Springer
Year: 1995
Tongue: English
Weight: 816 KB
Volume: 2
Category: Article
ISSN: 1068-9265
DOI: 10.1007/bf02307090

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II dose-escalation study of ex

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

✍ Christopher W. Ryan; Walter M. Stadler; Nicholas J. Vogelzang 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

Phase II Study of CI-958 in Patients wit

Phase II Study of CI-958 in Patients with Hormone Refractory Prostate Carcinoma

✍ J. Philip Kuebler; Timothy Moore; James Pritchard; Eric Kraut 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 44 KB

A Phase I/II study of weekly paclitaxel

A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

✍ Anna C. Ferrari; Abraham Chachoua; Harvinder Singh; Mark Rosenthal; Samir Taneja 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

Fixed higher dose schedule of suramin pl

Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma : A multicenter Phase II study

✍ Emiliano Calvo; Javier Cortés; Javier Rodríguez; Manuel Sureda; César Beltrán; J 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

135 - Phase II study of vlnorelbine in p

135 - Phase II study of vlnorelbine in patients with hormone refractory prostate cancer

✍ A. Caty; S. Oudard; Y. Humblet; M. Beauduin; E. Suc; Th. Gil; F. Rolland; Ph. Ho 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Phase II study of the oral cyclophospham

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. Chrétien; Sy 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum